Peptidomimetic inhibitors of HIV protease
- PMID: 15193140
- DOI: 10.2174/1568026043388330
Peptidomimetic inhibitors of HIV protease
Abstract
There are currently (July, 2002) six protease inhibitors approved for the treatment of HIV infection, each of which can be classified as peptidomimetic in structure. These agents, when used in combination with other antiretroviral agents, produce a sustained decrease in viral load, often to levels below the limits of quantifiable detection, and a significant reconstitution of the immune system. Therapeutic regimens containing one or more HIV protease inhibitors thus provide a highly effective method for disease management. The important role of protease inhibitors in HIV therapy, combined with numerous challenges remaining in HIV treatment, have resulted in a continued effort both to optimize regimens using the existing agents and to identify new protease inhibitors that may provide unique properties. This review will provide an overview of the discovery and clinical trials of the currently approved HIV protease inhibitors, followed by an examination of important aspects of therapy, such as pharmacokinetic enhancement, resistance and side effects. A description of new peptidomimetic compounds currently being investigated in the clinic and in preclinical discovery will follow.
Similar articles
-
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography.Ther Drug Monit. 2005 Apr;27(2):186-92. doi: 10.1097/01.ftd.0000152680.36517.5d. Ther Drug Monit. 2005. PMID: 15795650
-
Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.HIV Clin Trials. 2006 Jul-Aug;7(4):163-71. doi: 10.1310/hct0704-163. HIV Clin Trials. 2006. PMID: 17065028
-
Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.Drugs. 2005;65(5):633-59. doi: 10.2165/00003495-200565050-00005. Drugs. 2005. PMID: 15748098 Review.
-
Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.J Mol Graph Model. 2010 Jan;28(5):455-63. doi: 10.1016/j.jmgm.2009.10.005. Epub 2009 Oct 30. J Mol Graph Model. 2010. PMID: 19931478
-
HIV-1 protease inhibitors. A review for clinicians.JAMA. 1997 Jan 8;277(2):145-53. JAMA. 1997. PMID: 8990341 Review.
Cited by
-
Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.FEBS J. 2010 Sep;277(18):3699-714. doi: 10.1111/j.1742-4658.2010.07771.x. Epub 2010 Aug 2. FEBS J. 2010. PMID: 20695887 Free PMC article.
-
HIV protease inhibitors in gut barrier dysfunction and liver injury.Curr Opin Pharmacol. 2014 Dec;19:61-6. doi: 10.1016/j.coph.2014.07.008. Epub 2014 Aug 6. Curr Opin Pharmacol. 2014. PMID: 25105480 Free PMC article. Review.
-
An inhibitor of HIV-1 protease modulates constitutive eIF2α dephosphorylation to trigger a specific integrated stress response.Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):E117-26. doi: 10.1073/pnas.1514076113. Epub 2015 Dec 29. Proc Natl Acad Sci U S A. 2016. PMID: 26715744 Free PMC article.
-
Therapeutic potential of HIV-1 entry inhibitor peptidomimetics.Exp Biol Med (Maywood). 2021 May;246(9):1060-1068. doi: 10.1177/1535370221990870. Epub 2021 Feb 17. Exp Biol Med (Maywood). 2021. PMID: 33596698 Free PMC article. Review.
-
Structural characterization of the feline-immunodeficiency-virus envelope glycoprotein 36 ectodomain for the development of new antivirals.Biochem J. 2005 Jul 15;389(Pt 2):559-67. doi: 10.1042/BJ20050103. Biochem J. 2005. PMID: 15799719 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
